PMI-supported study aims to measure malaria among pregnant women in Rwanda

Jan 25 2012NewsGuard 100/100 Score

This post in the Malaria Free Future blog reports on a study underway in Rwanda that aims to measure the prevalence of malaria in pregnancy (MIP). The research is supported by the U.S. President's Malaria Initiative (PMI) and is being carried out through its Maternal and Child Health Integrated Program (MCHIP) "so that the National Malaria Control Program (NMCP) can have data to design appropriate MIP interventions as the country moves towards malaria elimination," the blog notes. According to the blog, the study of more than 4,000 women "focuses on pregnant women during their first visit to focused antenatal care (FANC) for their current pregnancy" and is currently at the half way mark (Brieger, 1/25).

Print

    http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

    Posted in: Women's Health News | Healthcare News

    Tags: , , , ,

    Comments (0)

    Suggested Reading

    Uncovering the secrets of malaria parasite cell division
    Maternal antibodies may hinder malaria vaccine effectiveness in infants
    Surge in malaria cases linked to aircraft-transported mosquitoes
    Malaria crystal structure offers clues for more effective medications
    Breakthrough discovery could lead to novel malaria vaccines and therapies
    New test promises to end malaria
    Deforestation drives a surge in malaria cases in the Amazon
    Study finds artemisinin resistance in African children with severe malaria

    Comments

    The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
    Post a new comment
    (Logout)
    Post

    Newsletters you may be interested in

    See all Newsletters »

    Terms

    While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

    Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

    Please do not ask questions that use sensitive or confidential information.

    Read the full Terms & Conditions.

    Provide Feedback

    You might also like...
    New drug MED6-189 shows promise against drug-resistant malaria